Managing Type 2 Diabetes with Oral GLP-1 Agonist, Orfoglipron
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on October 8th, 2025
|
Activation of GLP-1 receptors is a well-established strategy for managing type 2 diabetes, with agents such as semaglutide and tirzepatide also showing benefits for weight loss and cardiovascular health. However, their use is complicated by the need for injection. Orfoglipron, a small-molecule oral GLP-1 receptor agonist, offers a potentially simpler alternative. Supported by Eli Lilly, a study was conducted to evaluate its efficacy in type 2 diabetes.
The phase 3 clinical trial enrolled 559 treatment-naïve patients whose diabetes was inadequately controlled by lifestyle modification alone. At baseline, participants had a mean glycated hemoglobin (HbA1c) level of 8% and an average body weight of 90.2 kg. They were randomized to receive placebo or orfoglipron at daily doses of 3 mg, 12 mg, or 36 mg.
After 40 weeks, orfoglipron significantly reduced HbA1c in a dose-dependent manner. Patients on the 36 mg dose achieved a 1.47% reduction in HbA1c, compared to just 0.41% in the placebo group. The highest dose also produced notable secondary benefits, including an average 8% reduction in body weight and significant decreases in triglycerides, VLDL, and LDL cholesterol. However, gastrointestinal adverse events were more common at higher doses, leading to treatment discontinuation in some patients. The authors emphasized the need for future trials to include patients previously treated with other glucose-lowering therapies and to directly compare orfoglipron with established GLP-1 receptor agonists to guide clinical use.
The phase 3 clinical trial enrolled 559 treatment-naïve patients whose diabetes was inadequately controlled by lifestyle modification alone. At baseline, participants had a mean glycated hemoglobin (HbA1c) level of 8% and an average body weight of 90.2 kg. They were randomized to receive placebo or orfoglipron at daily doses of 3 mg, 12 mg, or 36 mg.
After 40 weeks, orfoglipron significantly reduced HbA1c in a dose-dependent manner. Patients on the 36 mg dose achieved a 1.47% reduction in HbA1c, compared to just 0.41% in the placebo group. The highest dose also produced notable secondary benefits, including an average 8% reduction in body weight and significant decreases in triglycerides, VLDL, and LDL cholesterol. However, gastrointestinal adverse events were more common at higher doses, leading to treatment discontinuation in some patients. The authors emphasized the need for future trials to include patients previously treated with other glucose-lowering therapies and to directly compare orfoglipron with established GLP-1 receptor agonists to guide clinical use.